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Androgen deprivation therapy (ADT) for prostate cancer (PCa) increases risk of type 2 diabetes (T2DM); however the associa-
tion between types and duration of ADT has not been fully elucidated. We examined how type and duration of ADT affects risk
of T2DM. Using data from Prostate Cancer database Sweden (PCBaSe) we investigated risk of T2DM in a cohort of 34,031 men
with PCa on ADT; i.e., anti-androgens (AA), orchiectomy, or gonadotropin-releasing hormone (GnRH) agonists compared to an
age-matched, PCa-free comparison cohort (n5167,205) using multivariate Cox proportional hazard regression. T2DM was
defined as a newly filled prescription for metformin, sulphonylurea, or insulin in the Prescribed Drug Register. A total of
21,874 men with PCa received GnRH agonists, 9,143 AA and 3,014 underwent orchiectomy. Risk of T2DM was increased in
men in the GnRH agonists/orchiectomy group during the first 3 years of ADT [i.e., 121.5 years HR: 1.61 (95%CI:
1.3621.91)], compared to PCa-free men. The risk decreased thereafter (e.g., 324 years HR: 1.17 (95% CI: 0.9821.40)).
Conversely, no increased risk was seen in men on AA (HR: 0.74 (95%CI: 0.6520.84). The incidence of T2DM per 1,000
person-years was 10 for PCa-free men, 8 for men on AA, and 13 for men on GnRH agonists/orchiectomy. Duration of ADT has
a significant impact on risk of T2DM. With the peak after three years of treatment, our data indicates that men on ADT, even
for a limited period of time, such as adjuvant to radiotherapy, are at increased risk of T2DM.
Androgen Deprivation Therapy (ADT) is the recommended ﬁrst
line treatment in all men with disseminated prostate cancer (PCa)
and is also used in conjunction with radiotherapy in locally
advanced disease as both neoadjuvant and adjuvant therapy.1
When men progress to castrate resistance, it is recommended that
treatment with ADT continues, alongside the addition of further
therapies. Given the prolonged disease trajectory of PCa, men can
remain on ADT for many years,2 making any long-term effects
associated with treatment signiﬁcant.
Common adverse effects of ADT include fatigue, hot
ﬂushes and impotence.3 ADT also increases the risk of car-
diovascular disease,4,5 reduces bone mineral density,6
increases risk of fractures and of type 2 diabetes (T2DM), as
demonstrated by several North American cohorts.7–10 This
led the Food and Drug Administration (FDA) in 2010 to add
a risk label on gonadotropin-releasing hormone (GnRH) ago-
nists for increased risk of T2DM and certain cardiovascular
diseases (heart attack, sudden cardiac death, and stroke).11
ADT increases the prevalence of metabolic syndrome com-
ponents such as decreased insulin sensitivity and increased
body fat.12 We have previously undertaken a meta-analysis to
quantify the association between ADT and metabolic syn-
drome.13 The risk of metabolic syndrome for men on ADT
increased almost two-fold, relative risk (RR) 1.75 (95% CI 1.27-
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2.41), as compared to men not on ADT. For T2DM this rela-
tive risk was 1.36 (95% CI 1.17-1.58). Here, we investigate the
risk of T2DM in men on ADT taking into account the impact
of different types and durations of ADT (GnRH agonists, anti-
androgens (AA), and orchiectomy) on risk of T2DM.
Methods
Study population and data collection
PCBaSe Sweden 3.0 is based on the National Prostate Cancer
Register (NPCR) of Sweden, which became nationwide in
1998 and covers 98% of all newly diagnosed cases of PCa, as
compared to the Swedish Cancer Register.14,15 NPCR includes
information on date of diagnosis, age at diagnosis, tumour
stage and differentiation, serum levels of prostate speciﬁc anti-
gen (PSA) at time of diagnosis, and primary treatment within
6 months after date of diagnosis. Risk categories were deter-
mined according to a modiﬁed version of the National Com-
prehensive Cancer Network Guideline16 as follows: Low risk:
T1-2, Gleason score of 2–6 and PSA< 10 ng/ml; intermediate
risk: T1-2, Gleason score 7 and/or PSA 10–20 ng/ml; high
risk: T3and/or Gleason score 8–10 and/or PSA 20—50 ng/ml;
regionally metastatic/locally advanced:T4 and/or N1 and/or
PSA 50–100 ng/ml in the absence of distant metastases (M0
or MX); distant metastases: M1 and/or PSA> 100 ng/ml.
Using the Swedish 10-digit personal identity number, ﬁve
PCa-free men from the general population in Sweden were
randomly selected within sets of men who matched the index
case on birth year and county of residence and included in the
PCBaSe comparison cohort.14 Cases and the comparison
cohort in PCBaSe were subsequently linked to a series of
national health care registers and demographic databases, in
order to obtain data on comorbidity, socioeconomic status,
and cause of death. Information on ﬁlled prescriptions of anti-
androgens (AA), gonadotropin-releasing hormone (GnRH)
agonists, metformin, sulphonylurea and insulin was obtained
from The National Prescribed Drug Register using ATC codes
(insulin- ANA, metformin- A10BA/BD sulphonylurea- A10BB
GnRH –L02AE AA- L02BB).17 The Research Ethics Board at
Umeå University approved this study.
For this analysis we selected both men who received pri-
mary and secondary ADT, i.e., as a second line treatment
strategy initiated after primary treatment at the time of dis-
ease progression. Primary treatment was recorded in NPCR
as well as the Prescribed Drug Register, whereas secondary
ADT was retrieved from the Prescribed Drug Register only.14
Co-morbidities were measured by the Charlson Comorbidity
Index (CCI), which assigns weights to a number of medical
conditions, including diabetes and hypertension based on dis-
charge diagnoses in the Patient Register.18 Each condition
was assigned a score of 1, 2, 3, or 6 and the ﬁnal CCI is giv-
en as the sum of these scores. Individuals were grouped into
CCI categories for ﬁnal scores of 0, 1, 2, or 31. Information
on age at diagnosis, primary treatment, education status, and
prostate cancer risk category were also used.
Analysis
We conducted an analysis whereby PCa men on ADT and
PCa-free men were followed to identify occurrence of T2DM.
The latter was deﬁned by two ﬁlled prescriptions for insulin,
metformin or sulphonylurea with a maximum time between
the two prescriptions of 180 days. The date of the ﬁrst ﬁlled
prescription was used as the date of the event. Hazard ratios
(HRs) for T2DM were calculated for men with PCa versus the
comparison cohort with left truncation using a Cox propor-
tional hazards model with age as a timescale accounting for
CCI, PCa risk category and education status. Left truncation
was applied because the Prescribed Drug Register started on
July 1st 2005. We allowed for a run-in period of six months
and men with a ﬁlled prescription for anti-diabetic drugs dur-
ing this period were excluded from the analysis. Hence, all
men with prevalent T2DM on an anti-diabetic drug were
excluded. Follow up started on 1st January 2006 and ended at
date of death, date of emigration, date of T2DM prescription,
or 31 December 2013, whichever came ﬁrst. Men who received
AA or GnRH according to NPCR and had a date of diagnosis
prior to 1st January 2006 and were found to still be receiving
them according to the Prescribed Drug Register during the
“run in period” were considered to have been “exposed” since
the date of diagnosis.15 All other exposure to AA or GNRH
was deﬁned as time from ﬁrst ﬁlled prescription. In case of
cross over, patients were allowed to change groups and were
from then onwards considered to be exposed to the treatment
in their new group. Thereby, these persons contributed per-
son/years in each treatment category.
The association between duration of ADT and risk of
T2DM was assessed using multivariate Cox proportional haz-
ards models with left truncation in which exposure time was
divided into the following intervals: 0–6 months, 6–12
What’s new?
All treatments involve tradeoffs. For patients with prostate cancer, treatment with androgen deprivation therapy (ADT) can lead
to an increased risk of type II diabetes. These authors set out to analyze how the duration of treatment, and the type of ADT,
affect diabetes risk. They collected data on patients receiving three types of ADT: anti-androgens, gonadotropin releasing hor-
mone agonists, and orchiectomy, and compared them with age-matched, cancer-free controls. The risk of diabetes peaked
after 3 years of treatment with GnRH agonists or orchiectomy. By contrast, patients receiving anti-androgens showed no
increase in diabetes risk relative to cancer-free controls.
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months, 12–18 months, 18–24 months, 24–30 months, 30–36
months, 36–48 months, 48–60 months, 60–72 months, 72–84
months, 84–120 months, >120 months. We also calculated
incidence rates per 1,000/person years for the different expo-
sure groups. Finally, we conducted a sensitivity analysis in
which incidence rates of T2DM were compared between men
with PCa 2 years prior to initiation of ADT and men 2 years
post initiation of ADT. This analysis included men free of
T2DM who received their ﬁrst ADT after 1st of August 2008 to
ensure that sufﬁcient data was available from the National Pre-
scribed Drug Register which only start on 1st July 2005.Those
men in the sensitivity analysis who developed T2DM in the
period 0–2 years prior to ADT were obviously not included in
the overall analysis. All data management was performed with
SAS version 9.3 (SAS Institute, Cary, NC) and all data analysis
was conducted with R version 2.13.2 (R Foundation for Statisti-
cal Computing, Wien, Austria).
Results
167,205 PCa-free men and 34,031 men with PCa out of
whom 21,874 (64%) received GnRH agonists, 9,143 (27%)
AA and 3,014 (9%) underwent orchiectomy were included in
the study (Table 1). Results for men who had undergone sur-
gical or medical castration were analyzed together in the
GnRH/Orch group.
There was a ﬁve-fold higher occurrence of metastatic dis-
ease at date of diagnosis among men in the GnRH compared
to men on AA (32% vs. 6%). Conversely, ﬁve times as many
men on AA had undergone primary curative treatment and
subsequently received ADT, compared to men on GnRH
(31% vs. 6%) (Table 1).
Table 2 shows the number of events and HRs for men
receiving a new prescription for insulin, sulphonylurea or met-
formin on AA or GnRH/Orch over time compared to a PCa
free cohort. Those in the GnRH/Orch group had an increased
risk, up until 2.5–3 years of exposure, HR 12 1.5 years of
ADT 1.61 (95% CI 1.362 1.91), 22 2.5 years of ADT 1.68
(95% CI:1.42 2.02), 2.5–3 years of ADT 1.42 (95% CI
1.162 1.76) which then reduced, 3–4 years of ADT 1.17 (95%
CI0.982 1.40) and 7–10 years ADT 0.96 (95% CI 0.772 1.19).
In contrast, those on AA had no increased risk of T2DM dur-
ing any time period compared to PCa-free men, HR during 0–
2 years of ADT 0.73 (95% CI: 0.612 0.87), 2–4 years: 0.71
(95% CI 0.562 0.91) and >4 years 0.80 (95% CI 0.612 1.05).
In the subgroup of men treated with insulin only (Table
2) there was a persistent increase in risk observed during all
time periods for men in the GnRH/Orch group, peaking at
2.5–3 years with a HR of 2.32 (95% CI: 1.672 3.21). In con-
trast, those on AA had no increased risk of T2DM during
any time period compared to PCa-free men.
Table 2 reports the corresponding results for those receiv-
ing either metformin or sulphonylurea. Those in the GnRH/
Orch group had a signiﬁcantly elevated risk until 22 2.5
years of exposure (HR: 1.65 (95%CI: 1.352 2.02) before a
reduction in later time periods and became nonstatistically
signiﬁcant. Similarly to insulin, no increased risk of T2DM
was seen in those on AA at any time period. The time-
dependent results of Table 2 are also illustrated in Figure 1.
The incidence of T2DM for those without ADT was 10/
1,000 person-years, for men on GnRH agonists/orchiectomy
13/1,000 person-years and 8/1,000 person-years for men on
AA (Table 3). The results of the sensitivity analysis compar-
ing the incidence of T2DM in men with PCa 2 years prior
and after initiation of ADT are presented in Table 4. A simi-
lar increase in risk for T2DM was observed. In men treated
with AA the incidence of T2DM (receiving insulin) was 1.5
vs. 1.7/1,000 person-years 2 years before and after ADT. In
those treated with GnRH/Orch, the incidence of T2DM
(receiving insulin) was 2.2 vs. 5.0/1,000 person-years, respec-
tively, and for T2DM (receiving metformin/sulfonylurea) 11.1
vs. 11.3/1,000 person-years.
Discussion
In accordance with previous studies, this large nation-wide pop-
ulation-based cohort study showed that men on ADT had an
increased risk of T2DM as deﬁned by ﬁlled prescriptions for an
anti-diabetic drug In addition, the highest risk of T2DM was
reached at 3 years after the start of GnRH/Orch. In contrast,
men on monotherapy anti-androgens had no such increase.
In the ﬁrst study on risk of T2DM for men on GnRH ago-
nists, Keating et al. showed an increased risk in men aged >66
with loco-regional PCa (HR for GnRH agonists versus no ADT:
1.44, 95% CI: 1.34-1.55).7 However, this study had a relatively
short duration of exposure, i.e., 1–4, 5–12, 13–24, >25 months.
The same authors obtained similar results in a further study
including men of all ages with loco-regional PCa.10 They ana-
lyzed combined androgen blockade and AA separately and did
not show an increased risk of T2DM. The effect of duration of
treatment on risk of T2DM was not examined. A similar study
was conducted by Alibhai et al. in a Canadian cohort of men
aged 66 years who received at least 6 months of ADT.8 They
also reported an increased risk of T2DM (HR: 1.16, 95% CI:
1.112 1.21), but did not examine GnRH and AA separately
and combined all forms of ADT as a single exposure. There was
a trend toward increased risk of diabetes with longer exposure
to ADT (HR for ADT vs. no ADT: 1.09, 95% CI: 0.92 1.08>24
months of exposure compared with HR: 0.99, 95% CI
0.902 1.08 at 6–24 months).
The longest duration of follow up to date was 25 months.7
No studies have looked at different types of ADT and the effect
of duration combined. AA use in North America is substantially
lower than in Europe, so there are little data from these cohorts
on AA. We examined the risk of T2DM with up to ten years of
exposure, which is to our knowledge the longest exposure stud-
ied to date. The highest risk associated with GnRH agonists
occurred relatively early and started to decline after 3 years of
treatment. For AA we did not observe an increased risk.
The observed temporal changes in risk ﬁt with the physio-
logical and metabolic changes previously described for GnRH
agonist treatment.19 These changes include increased fat
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Table 1. Baseline characteristics of men with PCa on ADT and the matched comparison cohort of PCa-free men in Prostate Cancer Data Base
3.0
PCa Free Cohort
All men with
PCa AA GnRH Orchiectomy
n (%) 167,205 34,031 9,143 21,874 3,014
Mean Follow up time (SD)
4.2 (2.5) 3.5 (2.4) 3.6 (2.3) 3.5 (2.4) 3.1 (2.4)
Age
Mean age at diagnosis (SD) 74.8 (8.5) 74.4 (8.4) 71.2 (8.0) 75.2 (8.3) 78.4 (7.3)
<65 23183 (13.9) 4908 (14.4) 2119 (23.2) 2623 (12.0) 166 (5.5)
65-74 55348 (33.1) 11806 (34.7) 3893 (42.6) 7247 (33.1) 666 (22.1)
75-84 70809 (42.3) 14136 (41.5) 2829 (30.9) 9655 (44.1) 1652 (54.8)
851 17865 (10.7) 3181 (9.3) 302 (3.3) 2349 (10.7) 530 (17.6)
Age at start of ADT
<65 - - 3592 (10.6) 1189 (13.0) 2254 (10.3) 149 (4.9)
65-74 - - 10849 (31.9) 3641 (39.8) 6596 (30.2) 612 (20.3)
75-84 - - 15493 (45.5) 3766 (41.2) 10059 (46.0) 1668 (55.3)
851 - - 4097 (12.0) 547 (6.0) 2965 (13.6) 585 (19.4)
Entry into PCBaSe
cohort/Year of PCa diagnosis
1997-2001 17889 (10.7) 5389 (15.8) 1145 (12.5) 3687 (16.9) 557 (18.5)
2002-2005 49375 (29.5) 11281 (33.1) 2738 (29.9) 7446 (34.0) 1097 (36.4)
2006-2009 64085 (38.3) 11567 (34.0) 3438 (37.6) 7161 (32.7) 968 (32.1)
2010-2012 35856 (21.4) 5794 (17.0) 1822 (19.9) 3580 (16.4) 392 (13.0)
CCI
0 110713 (66.2) 22328 (65.6) 6271 (68.6) 14143 (64.7) 1914 (63.5)
1 29651 (17.7) 6247 (18.4) 1587 (17.4) 4048 (18.5) 612 (20.3)
2 15948 (9.5) 3309 (9.7) 793 (8.7) 2215 (10.1) 301 (10.0)
31 10893 (6.5) 2147 (6.3) 492 (5.4) 1468 (6.7) 187 (6.2)
Education Status
Low 78732 (47.1) 16239 (47.7) 3559 (38.9) 10898 (49.8) 1782 (59.1)
Middle 56051 (33.5) 11579 (34.0) 3422 (37.4) 7252 (33.2) 905 (30.0)
High 29171 (17.4) 5771 (17.0) 2091 (22.9) 3403 (15.6) 277 (9.2)
Missing 3251 (1.9) 442 (1.3) 71 (0.8) 321 (1.5) 50 (1.7)
PCa risk category
No PCa 167205 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1. Low risk - - 2334 (6.9) 1180 (12.9) 1068 (4.9) 86 (2.9)
2. Intermediate risk - - 6021 (17.7) 2819 (30.8) 2929 (13.4) 273 (9.1)
3. High risk - - 11775 (34.6) 3469 (37.9) 7410 (33.9) 896 (29.7)
4. Regionally metastatic - - 4745 (13.9) 962 (10.5) 3354 (15.3) 429 (14.2)
5. Distant metastases - - 8850 (26.0) 591 (6.5) 6956 (31.8) 1303 (43.2)
6. Missing data - - 306 (0.9) 122 (1.3) 157 (0.7) 27 (0.9)
Primary Treatment
No PCa 167205 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
ADT - - 24815 (72.9) 4113 (45.0) 17972 (82.2) 2730 (90.6)
Curative treatment - - 4352 (12.8) 2887 (31.6) 1402 (6.4) 63 (2.1)
Deferred treatment - - 4864 (14.3) 2143 (23.4) 2500 (11.4) 221 (7.3)
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mass, reduced lean body mass and increased insulin levels,
which all have been demonstrated to occur within 3 months
of commencing ADT.19–21 Lee et al. measured lean body
mass and fat mass in 65 men with PCa on GnRH agonists over
a 12 month period. Those with longer prior exposure to
treatment with GnRH agonists had less fat accumulation and less
loss of lean body mass over the 12 month period.20 Similarly,
GnRH agonists decrease sensitivity to insulin within 3 months of
ADT start.22 Thus, the adverse metabolic effects of GnRH ago-
nists occur within months of initiation; the consequences of these
changes (i.e., developing T2DM) do not peak until 2 years later.
Strengths of our study are its large size, population-based
design of PCBaSe, and long duration of exposure to ADT.
The use of an age-matched PCa-free comparison cohort
allowed us to handle PCa heterogeneity. If we had used men
with PCa receiving radical therapy or men on active surveil-
lance/watchful waiting as the comparison group we would
have introduced selection bias as these men have a different
general health status than men with PCa on ADT. However,
this approach does not allow us to tease out the disease effect.
The sensitivity analysis comparing incidence rates of T2DM
in men with PCa 2 years prior and after initiation of ADT
aimed to assess this. The results remained consistent to what
was seen when using the PCa free comparison cohort, with a
higher incidence of T2DM in those receiving insulin observed
after 2 years of GnRH treatment (2.2 vs. 5.0/1,000 person
years) and not in those treated with AA.
One limitation of this study is that by using new drug pre-
scriptions as a proxy for T2DM, we have missed all T2DM
cases treated by diet alone; however, this would be similar for
Figure 1. Graphical representation of risk of T2DM by time on
GnRH agonists, T2DM was defined by anti-diabetic drug prescrip-
tions: (a) Insulin, (b) Sulphonluurea or Metaformin, (c) Insulin,
Sulphonylurea or Metformin. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
Table 3. Incidence of T2DM per 1,000 person-years in PCa-free men and men with PCa on anti-androgens (AA) or GnRH agonists/orchiectomy
(GnRH/Orch group). according to anti-diabetic drug prescriptions.
Insulin/Sulphonylurea
/Metformin Insulin
Metformin
/Sulphonylurea
No of events Incidence rate No of events Incidence rate No of events Incidence rate
No ADT 7274 10.45 1030 1.47 6244 8.97
AA 239 8.07 33 1.11 206 6.96
GNRH/Orch 1258 12.98 287 2.96 971 10.01
Prior AA 81 13.64 11 1.85 70 11.79
No Prior AA 1177 12.93 276 3.03 901 9.90
Table 4. Event number and incidence per 1,000/person years of T2DM treated with Metformin/Sulphonylurea or Insulin in men with PCa two
years before and after ADT initiation.
Metformin/Sulphonylurea Insulin
2 years prior to ADT
initiation
2 years after ADT
initiation
2 years prior to ADT
initiation
2 years after
ADT initiation
Type of ADT at initiation
No DM
events
Incidence
of DM
No DM
events
Incidence
of DM
No DM
events
Incidence
of DM
No DM
events
Incidence
of DM
All 394 10.4 301 10.1 73 1.9 113 3.8
AA 128 9.1 91 8.1 21 1.5 19 1.7
AA initial treatment 50 9.2 44 9.5 10 1.8 10 2.2
AA deferred treatment 78 9.0 47 7.1 11 1.3 9 1.4
GNRH 266 11.1 210 11.3 52 2.2 94 5.0
GNRH initial treatment 195 10.9 159 11.3 41 2.3 70 5.0
GNRH deferredtreatment 71 11.7 51 11.2 11 1.8 24 5.2
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men with and without PCa. It would be interesting in future
studies to be able to include this group of men. By only includ-
ing two of the potential oral hypoglycaemic agents used for
T2DM, metformin and sulphonylurea, we missed those with
T2DM who were on alternative drugs. However, these only
accounted for 1.32% of events. Another limitation of this study
is that we did not have information about lifestyle factors
including weight or family history of T2DM. However, all
results were adjusted for CCI, which accounts for other comor-
bidities associated with lifestyle risk factors,23 as well as educa-
tion status—which has also been shown to be a good indicator
of baseline health status.23 Despite adjusting for several covari-
ates, residual confounding may still be present. However,
adjustment for CCI and education status reduces this possibili-
ty substantially. A further limitation is that the different risks
observed between GnRH agonists and AA could potentially be
explained by selection bias, rather than a real difference in the
two treatments. Men treated with GnRH agonists are not only
more likely to have locally advanced or distantly metastatic dis-
ease, they are also more likely to have more comorbidities than
those treated with AA. Men on AA had lower PSA and T stage
than those initially treated with GnRH agonists (data not
shown). This reﬂects standard clinical practice whereby GnRH
agonists are used as a primary treatment for advanced disease.
Hence, men on GnRH agonists may be at higher risk of T2DM
than those on AA; this however, does not diminish the clinical
importance of identifying those at highest risk of T2DM during
ADT.
Conclusion
Duration of GnRH agonists had a signiﬁcant impact on risk
of T2DM in men with PCa, with the peak risk observed after
3 years of treatment. This suggests that even men receiving
adjuvant ADT, for a short time period, may be at increased
risk of T2DM.
Disclaimer
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